To The Moon

When a company delivers a blockbuster quarter yet suffers the largest one-day share price collapse in its history, I instinctively wonder whether the market has become more emotional than analytical. That is precisely where Reddit finds itself. The company reported an exceptional second quarter, comfortably beating expectations on both revenue and earnings, only for investors to focus almost exclusively on one uncomfortable admission: Google's AI-powered search is changing how people find Reddit. Suddenly, Wall Street has split into two camps. One sees an overreaction to a temporary headwind. The other sees the first crack in the foundations of a premium growth stock. Both arguments deserve to be heard. When direction changes faster than fundamentals A Quarter That Should Have Been a Victo

The $1 Trillion Question: Did Wall Street Misread the Memory Crash? If there is one lesson I keep relearning in semiconductor investing, it is that the market has the memory of a goldfish until it suddenly remembers it is dealing with the memory industry. That is precisely what has happened to SK Hynix. Only weeks after completing the largest first-time US listing ever by a foreign company, with a Nasdaq ADR valued at roughly US$28–29 billion, the company found itself caught in one of the sharpest sentiment reversals of the AI era. A stock that had climbed roughly 220% before its July peak abruptly lost around 35%, joining a wider sell-off across $Micron Technology(MU)$, Samsung and $SanDisk Corp.(SNDK)$ as

Corning has survived world wars, recessions, technological revolutions and the collapse of entire industries. Yet one of the oldest companies on the New York Stock Exchange has just experienced its sharpest one-day share price fall since 30 July 2002—not because it missed earnings, but because it wasn't quite optimistic enough. That alone tells me everything about today's market. $Corning(GLW)$ delivered another strong quarter, with core earnings per share climbing 30% and comfortably beating expectations. The problem wasn't what the company achieved. It was what management expected next. Revenue guidance of $4.9-$5.0 billion landed fractionally below the market's expectation of around $5 billion, and investors wasted little time reminding everyone

Wall Street rarely admits it has no idea what a company is worth. Oklo is the exception. When analysts can justify price targets ranging from $14 to $140, they are not debating valuation models; they are debating reality. Either $Oklo Inc.(OKLO)$ evolves into the first successful commercial small modular reactor (SMR) developer of its kind, or it becomes another ambitious engineering story that never quite reaches escape velocity. The disagreement isn't confined to research notes. Oklo's shares surged to around $175 on a closing basis, while briefly touching almost $200 intraday last October, before suffering a sharp reset this year, illustrating just how quickly sentiment can swing when expectations run ahead of execution. At the same time, rough

The $267 Argument Isn't About AI – It's About Who Gets Paid CoreWeave isn't divided by opinion — it's divided by $267. That's the gap between Wall Street's lowest published price target of $36 and its highest of $303. When professionals studying the same filings arrive at valuations separated by nearly three hundred dollars, investors should pay attention. One company. Two futures. Wall Street cannot agree That extraordinary spread tells me this isn't a debate over whether artificial intelligence is real. It plainly is. The real argument is whether a specialist GPU cloud provider can generate attractive long-term returns while spending money at a pace that would make even the largest industrial companies pause for breath. This is why $CoreWeave, Inc.(

When unanimous optimism meets relentless scepticism When all 11 Wall Street analysts covering a stock rate it a Buy, you might expect investors to be piling in. Instead, $APPLIED DIGITAL CORP(APLD)$ has roughly 27% of its shares sold short, and after tumbling to around $30, even the most conservative analyst price target of $40 still implies roughly 33% upside. Either somebody is spectacularly wrong, or the market is seeing something the analysts aren't. One company. Two futures. One extraordinary disagreement That extraordinary disconnect makes Applied Digital one of the most fascinating battleground stocks in AI infrastructure today. This isn't the usual debate over whether artificial intelligence will change the world. Most investors agree it w

One share price, two completely different stories I rarely see a stock where Wall Street and the market appear to be reading entirely different scripts. Hims & Hers Health trades around $33, yet the consensus target from 13 analysts sits between $28 and $30, implying roughly 13% downside. At the bullish end, Canaccord Genuity recently lifted its target to $40. At the bearish end, one analyst believes the shares are worth just $21. That's a spread of more than 90% between the highest and lowest targets, and it tells me one thing above all else: nobody can agree what this business is actually worth. The market and Wall Street rarely disagree this dramatically. Perhaps the market still knows something analysts don't. Or perhaps investors have simply fallen in love with a compelling narrat

Has AI's biggest spending boom just become software's biggest headache? Watching $IBM(IBM)$ suffer its worst one-day share price collapse since records began in 1968 was rather like watching a seasoned marathon runner trip over the finishing tape. Few expected perfection, but almost nobody expected a 25%-plus plunge that erased roughly US$67 billion in market value before the company had even reported quarterly earnings. Yet I think the market may be asking the wrong question. The debate isn't simply whether IBM's AI turnaround has failed. It's whether the AI investment cycle itself has temporarily turned against the very software companies expected to benefit from it. That sounds absurd until you consider IBM's explanation. Enterprise customers ha

When Wall Street Can't Even Agree on Reality Every so often I come across a stock where the numbers tell one story and investors tell another. $Paramount Skydance Corp(PSKY)$ is one of those rare occasions. The company is covered by 27 analysts, yet only 52% rate it a Buy. That is effectively a coin toss for a company of this size. Even more striking, price targets range from just $2 to $20 a share, while the average target has quietly fallen by almost 10% over the past three months. That isn't normal disagreement over valuation. It's a disagreement over what Paramount Skydance will actually become. For me, that's what makes this one of the most fascinating investments in today's market. Investors aren't simply debating earnings; they're debating

Inside $Summit Therapeutics PLC(SMMT)$ $15 Billion Leap of Faith Every bull market eventually produces a stock that stops behaving like a company and starts behaving like a referendum. Right now, that stock may be Summit Therapeutics. On one side sit investors convinced ivonescimab is the most important oncology breakthrough in years. On the other are sceptics who see a company worth billions despite having virtually no commercial revenue and a single regulatory hurdle capable of changing everything overnight. The truth is that both camps have a point. And that is precisely why Summit has become one of Wall Street's most fascinating battlegrounds. Wall Street is pricing probabilities, not profits The Drug That Started the Argument Summit's investm